Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer

S Kageyama, H Ikeda, Y Miyahara, N Imai… - Clinical Cancer …, 2015 - AACR
Purpose: Preparative lymphodepletion, the temporal ablation of the immune system, has
been reported to promote persistence of transferred cells along with increased rates of tumor …

Safety and persistence of WT1-specific T-cell receptor gene− transduced lymphocytes in patients with AML and MDS

I Tawara, S Kageyama, Y Miyahara… - Blood, The Journal …, 2017 - ashpublications.org
Abstract Wilms' tumor 1 (WT1) is constantly expressed in leukemic cells of acute leukemia
and myelodysplastic syndrome (MDS). A T-cell receptor (TCR) that specifically reacts with …

Humoral immune responses in patients vaccinated with 1–146 HER2 protein complexed with cholesteryl pullulan nanogel

S Kageyama, S Kitano, M Hirayama, Y Nagata… - Cancer …, 2008 - Wiley Online Library
The CHP‐HER2 vaccine, comprising truncated 146HER2 protein complexed with nanogels
of cholesteryl pullulan (CHP), is a novel protein antigen vaccine that elicits 146HER2 …

HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan

S Kitano, S Kageyama, Y Nagata, Y Miyahara… - Clinical cancer …, 2006 - AACR
Purpose: We developed a complex of tumor antigen protein with a novel nanoparticle
antigen delivery system of cholesteryl pullulan (CHP). To target HER2 antigen, we prepared …

[HTML][HTML] Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of …

S Kageyama, H Wada, K Muro, Y Niwa, S Ueda… - Journal of translational …, 2013 - Springer
Background Cholesteryl pullulan (CHP) is a novel antigen delivery system for cancer
vaccines. This study evaluated the safety, immune responses and clinical outcomes of …

[HTML][HTML] NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome

M Ishihara, S Kitano, S Kageyama… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Because of the shortage of ideal cell surface antigens, the development of T-
cell receptor (TCR)-engineered T cells (TCR-T) that target intracellular antigens such as NY …

High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer …

T Saito, H Wada, M Yamasaki, H Miyata, H Nishikawa… - Vaccine, 2014 - Elsevier
Purpose We conducted a cancer vaccine clinical trial with MAGE-A4 protein. Safety, clinical
response, and antigen-specific immune responses were analyzed and the prognostic factors …

[HTML][HTML] Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY‑ESO‑1 and MAGE‑A4 in high‑grade soft‑tissue …

T Kakimoto, A Matsumine, S Kageyama… - Oncology …, 2019 - spandidos-publications.com
The aim of the present study was to explore the expression of the cancer testis antigens New
York‑esophageal squamous cell carcinoma (NY‑ESO)‑1 and melanoma‑associated antigen …

A phase 1 trial of NY‐ESO‐1‐specific TCR‐engineered T‐cell therapy combined with a lymph node‐targeting nanoparticulate peptide vaccine for the treatment of …

M Ishihara, Y Nishida, S Kitano, A Kawai… - … Journal of Cancer, 2023 - Wiley Online Library
The efficacy of immune checkpoint inhibitors is limited in refractory solid tumors. T‐cell
receptor gene‐modified T (TCR‐T)‐cell therapy has attracted attention as a new …

Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients

T Ishikawa, S Kageyama, Y Miyahara… - Cancer Immunology …, 2021 - Springer
The nanoparticle complex of cholesteryl pullulan (CHP) and NY-ESO-1 antigen protein
(CHP-NY-ESO-1) presents multiple epitope peptides to MHC class I and II pathways …